Apellis reports positive results for pegcetacoplan in phase 2 C3G trial

Apellis Pharmaceuticals has reported positive results for pegcetacoplan from the phase 2 DISCOVERY clinical trial in patients with C3 glomerulopathy (C3G), a type of kidney ... Read More